Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date — because we believe great analysis should be held accountable.

AllAAOIABUSABVXACADACRVADMAAGIOALMSALMUALTSAPGEARTVASXAUPHAVAVAVPTAXTIBCRXCAICAKECEGCELCCEPCGONCIENCNCCOGTCRCLCTMXCTRIDKNGDUOLFLUTGCTGLWGOOGGPCRHALOHCAHIMSHOODHWMIDYAIRENIVVDKALAKALVKRYSLENZLEVILITELQDALRMRLULULUNRMDGLMESOMIRMMOHMPWRMTCHMUMVSTNBISNKENRIXNUENVAXNXPIOKUROLMAONCONTOORKAOSCRPDFSPHATPOETPRLDPYGRBLXRDDTRIGLRKLBSGHCSPRYSRPTTARSTBPHTHTRVITSHATTMIUNHVEONVORWVEXFORZBIOZLABZYME
KalVista Pharmaceuticals (KALV) is a biopharmaceutical company whose core asset is EKTERLY®, the first FDA-approved oral, on-demand treatment for HAE. With its convenience, the drug is poised to disrupt the market and is the primary value driver. The company’s oral prophylactic drug in development offers long-term growth potential. Although the company faces risks from commercialization, fierce competition, and financial losses, this analysis views KALV as a high-risk, high-reward investment opportunity and assigns it a "Buy" rating.

Why KalVista Pharmaceuticals ($KALV) Could Deliver a 3× Return Within a Year

2025-07-12Change from report: +77.4%1M: -19.5%3M: -25.6%

KalVista Pharmaceuticals (KALV) is a biopharmaceutical company whose core asset is EKTERLY®, the first FDA-approved oral, on-demand treatment for HAE. With its convenience, the drug is poised to disrupt the market and is the primary value driver. The company’s oral prophylactic drug in development offers long-term growth potential. Although the company faces risks from commercialization, fierce competition, and financial losses, this analysis views KALV as a high-risk, high-reward investment opportunity and assigns it a "Buy" rating.